Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Liso-cel for second-line R/R aggressive large B-cell NHL

Nilanjan Ghosh • 18 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Lisocabtagene maraleucel
TRANSCEND-PILOT-017006

Nilanjan Ghosh MD, PhD, of Levine Cancer Institute, Charlotte, NC, updates us on results of the TRANSCEND-PILOT-017006 study (NCT03483103) investigating lisocabtagene maraleucel (liso-cel), a CD19 directed CAR-T cell therapy, for the treatment of second-line, transplant-ineligible relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nilanjan Ghosh

5:45
Treatment effectiveness of venetoclax-based therapy after BTKi exposure in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
6:05
Real-world data on the effect of ibrutinib flexible dosing treatment strategies on TTNT in CLL/SLL
Nilanjan Ghosh • 14 Dec 2023
5:42
Comparative effectiveness of liso-cel vs conventional 2L chemotherapy in R/R LBCL
Nilanjan Ghosh • 8 Dec 2022
5:59
InformCLL registry analysis: ibrutinib vs chemoimmunotherapy for the first-line treatment of CLL/SLL
Nilanjan Ghosh • 8 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals